Solabia accelerates expansion plan with three strategic acquisitions

Headquartered in Paris and founded in 1972, Solabia specialises in natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, food and clinical testing industries. Leveraging advanced biotechnology capabilities - including fermentation, enzymatic synthesis, plant extraction, and green chemistry - Solabia develops high-performance ingredients designed to meet complex formulation requirements and deliver differentiated outcomes for its global customer base.

These transactions represent Solabia’s first acquisitions since Astorg’s investment in October 2025 and mark an important milestone in the next phase of its development, underscoring Astorg’s deep healthcare expertise and entrepreneurial approach to building platforms in close partnership with management.

The acquisitions include:

• Mibelle Biochemistry (Switzerland), a developer and producer of science-backed natural active ingredients across skin care, healthy ageing, hair care and cognitive health, with distribution in more than 50 countries. The company specialises in transforming naturally derived compounds into clinically substantiated ingredients through proprietary, differentiated plant stem cell technology, further strengthening Solabia’s leadership position in high-performance natural actives.

• Seqens ’ Botanical Actives and In-Vitro Diagnostics Activity (France), a developer and manufacturer of botanical active ingredients for cosmetics, as well as plasma and serum solutions for diagnostics applications. The acquisition reinforces Solabia’s global position in botanical actives while securing critical raw material supply.

• Xebios Group (Germany and the Netherlands), a microbiological diagnostics solutions provider, with strong capabilities in water, food & beverage and clinical testing. The transaction expands Solabia’s European diagnostics footprint, enhances its product portfolio and broadens its innovation capacity in high-performance microbiology solutions.

Together, these acquisitions further strengthen Solabia’s position as one of the few biotechnology platforms operating at scale, combining deep technological expertise with strong global distribution capabilities. The combined group benefits from greater scale, expanded technical expertise and enhanced geographic reach, reinforcing Solabia’s ability to deliver differentiated, science-driven solutions to its global customer base across natural active ingredients and diagnostics.

Jean -Baptiste Dellon, Chief Executive Officer of Solabia, said:

“We are pleased to welcome Mibelle Biochemistry, Seqens’ Botanical Actives and IVD Activity, and Xebios teams to Solabia. Beyond their strong scientific and technical capabilities, we share a common culture of innovation, quality and long-term client commitment. With the backing of Astorg and TA Associates, we are expanding our ability to serve customers worldwide with a broader and more integrated portfolio of science-driven solutions across beauty, wellbeing and diagnostics. This marks an important step in strengthening Solabia’s position as a scaled, independent biotechnology platform and lays the foundation for continued growth.”

Nicolas Marien, Partner, and Paul Arhanchiague, Managing Director, at Astorg, added:

“Solabia exemplifies the type of specialised, innovation-driven platform we seek to back. Our deep healthcare and life sciences expertise enables us to assess and execute targeted transactions with conviction, while our entrepreneurial approach and close partnership with management support disciplined, long-term value creation. These acquisitions reflect that focus and mark a significant step in the continued execution of Solabia’s long-term growth strategy.”